ETCT Loncar Cancer Immunotherapy ETF chart

Last update: 2022-12-30
Key statistics and financials
Revenue per share N/A
Dividend & YieldN/A$ (N/A)
Beta N/A
Market capitalization N/A
Operating cash flow N/A
ESG Scores unknown

Company description

Sector: N/A - Industry: N/A


Insider Transactions

Here are the insider transactions of stock shares related to ETCT Loncar Cancer Immunotherapy ETF:

Filer Name Transaction Text Ownership Date Filer Relation Shares
NO DATA

Insider transaction explanations

Insider buying is the legal purchase of shares by a senior executive or director of a company. "Filer Name" corresponds to the name of the stock buyer or seller. "Transaction Text" describes the transaction. "Ownership" gives information about the transaction type. "Date" is the reported transaction date. "Filer Relation" gives the role of the insider in the company. "Shares" is the value of the transaction. You will find the complete description of the General Transaction Codes on the SEC dedicated page


Investment strategy backtesting

These are the result of three automatic investment systems applied to ETCT Loncar Cancer Immunotherapy ETF. You will find the performance of an systematic investment system, a momentum strategy, and a buy the dip trading strategy.


Systematic investment results on ETCT Loncar Cancer Immunotherapy ETF

Here is the result of two systematic investment strategies applied to ETCT Loncar Cancer Immunotherapy ETF. The first strategy automatically buys the first day of the month, and the second strategy buys the fifteenth day of the month.

Systematic investment equity curve on ETCT Loncar Cancer Immunotherapy ETF

The following chart shows the equity curve of the two systematic investment strategies applied to ETCT Loncar Cancer Immunotherapy ETF:

ETCT Loncar Cancer Immunotherapy ETF automated entries

The systematic investment strategy that buys the first day of the month would give a performance of 21.2% on the backtest period.

Performance at glance

Performance

21.2 %

Latent gain

372.67 $

Invested capital

1757.95 $

Annualized return

5.17 %
Build your Trading System
Automated Trading using Prorealtime ebook

Momentum strategy results on ETCT Loncar Cancer Immunotherapy ETF

This is the result of two momentum investment strategies applied to ETCT Loncar Cancer Immunotherapy ETF. The first strategy uses a momentum signal calculated on one quarter, and the second uses a momentum signal calculated on two quarters.

Momentum entry openings on ETCT Loncar Cancer Immunotherapy ETF

The following chart shows all the entries opened by the momentum investment system on ETCT Loncar Cancer Immunotherapy ETF:

ETCT Loncar Cancer Immunotherapy ETF momentum entries
  • The first momentum investment strategy would give 23.95% of return on ETCT Loncar Cancer Immunotherapy ETF. That represents 1320.81$ of latent gain with 5514.95$ of employed capital.
  • The second momentum investment strategy would give 28.73% of return on ETCT Loncar Cancer Immunotherapy ETF. That represents 1433.32$ of latent gain with 4988.14$ of employed capital.
Performance at glance (1Q Momentum)

Performance

23.95 %

Latent gain

1320.81 $

Invested capital

5514.95 $

Annualized return

19.33 %
Performance at glance (2Q Momentum)

Performance

28.73 %

Latent gain

1433.32 $

Invested capital

4988.14 $

Annualized return

7.94 %

Momentum equity curve on ETCT Loncar Cancer Immunotherapy ETF

The following chart shows the equity curve of the two momentum strategies applied to ETCT Loncar Cancer Immunotherapy ETF:

ETCT Loncar Cancer Immunotherapy ETF momentum equity

Note: the dividends potentially given by ETCT Loncar Cancer Immunotherapy ETF are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on ETCT Loncar Cancer Immunotherapy ETF

The following chart shows the employed capital evolution of the two momentum strategies on ETCT Loncar Cancer Immunotherapy ETF since the beginning:

ETCT Loncar Cancer Immunotherapy ETF

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Buy the dip strategy result on ETCT Loncar Cancer Immunotherapy ETF

Buy the dip entry openings on ETCT Loncar Cancer Immunotherapy ETF

ETCT Loncar Cancer Immunotherapy ETF

The performance achieved by the robo-advisor on ETCT Loncar Cancer Immunotherapy ETF is 40.6%. That represents 299.09$ of latent gain with 736.63$ of employed capital. The following chart shows ETCT Loncar Cancer Immunotherapy ETF stock price with all the entries opened by the automated investment system.

Note: The blue line represents the weekly stock price of ETCT Loncar Cancer Immunotherapy ETF, and the green triangles represent the entry openings. The artificall robo-advisor needs at least 100 weeks of trading history to work.

Performance at glance

Performance

40.6 %

Latent gain

299.09 $

Invested capital

736.63 $

Annualized return

19.33 %

Equity curve of the strategy applied to ETCT Loncar Cancer Immunotherapy ETF

The following chart shows the result of the investment strategy applied to ETCT Loncar Cancer Immunotherapy ETF:

ETCT Loncar Cancer Immunotherapy ETF

Note: the dividends potentially given by ETCT Loncar Cancer Immunotherapy ETF are not integrated into the calculation of the equity curve neither the performance of the strategy. The integration of the dividends will be available soon.


Employed capital on ETCT Loncar Cancer Immunotherapy ETF

The following chart shows the employed capital evolution since the beginning of the investment strategy on ETCT Loncar Cancer Immunotherapy ETF:

ETCT Loncar Cancer Immunotherapy ETF

Note: the algorithm buys for a maximum of 250$ per entry. If the stock price is greater than 250$, the system buys only one stock per entry. The investment system stops automatically when the financial exposure reaches 10000$.


Investment strategies comparison on ETCT Loncar Cancer Immunotherapy ETF

In this section, I will compare the three previous investment strategies applied to ETCT Loncar Cancer Immunotherapy ETF.

Equity curve comparison on ETCT Loncar Cancer Immunotherapy ETF

The following chart shows the equity curve of the artificall advisor, the trend folowing and the automatic investment strategies:

ETCT Loncar Cancer Immunotherapy ETF investment strategy comparison

Employed capital comparison on ETCT Loncar Cancer Immunotherapy ETF

ETCT Loncar Cancer Immunotherapy ETF investment comparison

Performance comparison on ETCT Loncar Cancer Immunotherapy ETF

Strategy Latent Profit Growth Employed capital CAGR
Automatic investment 21.2% 372.67$ 1757.95$ 5.17%
Momentum 1 quarter 23.95% 1320.81$ 5514.95$ 6.2%
Momentum 2 quarters 28.73% 1433.32$ 4988.14$ 7.94%
Non-directional 40.6% 299.09$ 736.63$ 19.33%
Annualized return comparison

Automatic investment

5.17 %

Momentum 1Q

7.94 %

Momentum 2Q

7.94 %

Non-directional

19.33 %

Correlated stocks

Here are the most positively and negatively correlated stocks with ETCT Loncar Cancer Immunotherapy ETF:

Note: The algorithm computes the probability of correlation between ETCT Loncar Cancer Immunotherapy ETF and the other stocks. There may be false positives or some missing correlated stocks. If the price of ETCT Loncar Cancer Immunotherapy ETF does not vary for 36 weeks, the correlation calculation result will be wrong.


Company information

Company name ETCT Loncar Cancer Immunotherapy ETF
Country
City
Address
Phone
Website
FullTime employees
Industry
Sector
Exchange XNAS
Ticker CNCR
Market www.nasdaq.com

ETCT Loncar Cancer Immunotherapy ETF ESG Scores

Environment scores

Environment ESG Factors Scores
Environment Score 0
Peer Environment Performance unknown
Environment Percentile unknown
Palm Oil unknown
Nuclear unknown
Fur Leather unknown
GMO unknown
Coal unknown
Pesticides unknown
Animal Testing unknown

Social scores

Social ESG Factors Scores
Social Score 0
Peer Social Performance unknown
Social Percentile unknown
Highest Controversy unknown
Peer Highest Controversy Performance unknown
Adult unknown
Gambling unknown
Alcoholic unknown
Tobacco unknown
Catholic unknown
Controversial Weapons unknown
Small Arms unknown
Military Contract unknown
Peer Count unknown

Related Controversy:


Governance scores

Governance ESG Factors Scores
Governance Score 0
Peer Governance Performance unknown
Governance Percentile unknown

ESG at glance
Total ESG Scores: unknown
Environment Score: 0
Social Score: 0
Governance Score: 0

ESG Performance: unknown

Peer Group: unknown

Peer Esg Score Performance: unknown

Rating Year: unknown

Rating Month: unknown

Max Age: unknown

Percentile: unknown